Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals announced that management will participate in upcoming investor conferences hosted by Wells Fargo and H.C. Wainwright in September. The company's pipeline includes FDA-approved XDEMVY for Demodex blepharitis and Phase 2 candidates for ocular rosacea and Lyme disease prevention.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.